Navigation Links
Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
Date:12/19/2007

CRANBURY, N.J., Dec. 19 /PRNewswire-FirstCall/ -- Amicus Therapeutics Inc. (Nasdaq: FOLD), a biopharmaceutical company developing small-molecule, orally administered pharmacological chaperones for the treatment of human genetic diseases, announced today positive results from its recently completed Phase 2 clinical trials of Amigal(TM) (migalastat hydrochloride) for Fabry disease. As of November 2007, Amigal is being developed in partnership with Shire Human Genetic Therapies (HGT), a business unit of Shire plc, which is focused on genetic diseases. The results will be discussed as a part of an "R&D Day" meeting being hosted by the company today from 4:30 to 7:00 PM at the Four Seasons Hotel in New York City. A live audio web cast of the presentation will be available to all interested parties through the Company's website at http://www.amicustherapeutics.com. Interested parties should connect at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to join the webcast. An archive of the webcast will be available at the same address until approximately January 2, 2008.

"The completion of these trials is a major milestone for Amicus and these clinical results represent an important proof of concept for the pharmacological chaperone platform technology," said John F. Crowley, President and CEO of Amicus Therapeutics. "We look forward to advancing our program in Fabry as well as Gaucher, Pompe, and other important therapeutic targets utilizing this new approach to the treatment of a wide range of human genetic diseases."

Summary of Study Results:

The primary objective of the Phase 2 trials was to evalu
'/>"/>

SOURCE Amicus Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...Dec. 2 According to the National I...ericans diagnosed with diabetes already have some ...hy, damage to the retina caused by leaky blood ves... diabetes and is one of the most feared diabetic c...tients who,ve had diabetes for 10 years or more wi...
(Date:12/1/2009)...Dec. 1 Reportlinker.com announces ...its catalogue: ,, Chromium - Global Market Tr.../Chromium---Global-Market-Trends.html ,, World...y stainless steel, while growth in aerospace and i...r growth of chromium metal. Environmental constrai...
(Date:12/1/2009)... Dec. 1 Harvest Technologies Corp....rom the company sponsored 60-patient clinical tria...hennai, India using the company,s BMAC System to t...mb Ischemia (CLI). Sri Ramachandra Medical Center ...itution based in Chennai, India and one of the lar...
(Date:12/1/2009)...ec. 1 /PRNewswire-Asia/ -- Shanghai ChemPartner, a...g China-based Contract Research,Organization (CRO)...tte,Technology Fast 50 China, ranking 3rd on the l...China. The award is a testament to ChemPartner,s o...2008. , The results of the 2009 Deloitte ...
Breaking Biology Technology:Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4Reportlinker Adds Chromium - Global Market Trends 2Reportlinker Adds Chromium - Global Market Trends 3Reportlinker Adds Chromium - Global Market Trends 4Reportlinker Adds Chromium - Global Market Trends 5Reportlinker Adds Chromium - Global Market Trends 6Reportlinker Adds Chromium - Global Market Trends 7Reportlinker Adds Chromium - Global Market Trends 8Reportlinker Adds Chromium - Global Market Trends 9Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 2Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 3Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 2Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 3
...jor steps toward putting quantum computers into re...m a qubit onto wires and transmitting the signal t... by a team of scientists at Yale. The accomplishme... September 20 and September 27, on which it is hig...k from a group at the National Institute of Standa...
...e 3% over Fiscal 2006 to $27.5 million - (all...noted), BELLEVILLE, ON, Sept. 26 /PRNewswire-Firs... research-based, technology-driven Canadian,biopha...ults for its 2007,fiscal year ended June 30, 2007....and commercial usage of,our E. coli O157:H7 cattle...
...astech,Pharmaceutical Company Inc. (Nasdaq: NSTK ...estor day in New York City on Thursday, October 4,...the Westin New York at Times,Square, on 270 West 4...entation from Steven C. Quay, M.D., Ph.D., Chairma...n Brandt, M.D., Executive Vice President,Clinical ...
Other Biology Technology:Yale scientists make 2 giant steps in advancement of quantum computing 2Yale scientists make 2 giant steps in advancement of quantum computing 3Bioniche Reports Fiscal 2007 Year-End Results 2Bioniche Reports Fiscal 2007 Year-End Results 3Bioniche Reports Fiscal 2007 Year-End Results 4Bioniche Reports Fiscal 2007 Year-End Results 5Bioniche Reports Fiscal 2007 Year-End Results 6Bioniche Reports Fiscal 2007 Year-End Results 7Bioniche Reports Fiscal 2007 Year-End Results 8Bioniche Reports Fiscal 2007 Year-End Results 9Bioniche Reports Fiscal 2007 Year-End Results 10Nastech to Host 2007 Analyst and Institutional Investor Day 2Nastech to Host 2007 Analyst and Institutional Investor Day 3
(Date:12/3/2009)...n of the upcoming forest deal at Copenhagen in ord...scientist at the University of Leeds. , Writing...least 50% of the carbon credit payments to be agre...s from Deforestation and Degredation), should be m...y rights assured. , "There is the potential here...
(Date:12/3/2009)...tment in energy efficient technologies research, b...cil (EPSRC) Chief Executive Dave Delpy believes th...earch has already brought us fuel cells, marine, w... is needed to develop the capabilities of differen...targets by 2020 and limit the impact of climate ch...
(Date:12/3/2009)...that occurred during the 2008-09 austral summer wa...for two main climate drivers, ENSO (El Nio - South...lar Mode), according to Dr. Marco Tedesco, Assista...e City College of New York. , Professor Tedesc... Graduate Center, added that Antarctic snowmelt le...
Breaking Biology News(10 mins):Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Research is vital to a cleaner, greener, low carbon future 2CCNY professor foresees rising Antarctic snowmelt 2Beckman Coulter Announces Third Quarter 2009 Results 5858 1Beckman Coulter Announces Third Quarter 2009 Results 5858 2Beckman Coulter Announces Third Quarter 2009 Results 5858 3Beckman Coulter Announces Third Quarter 2009 Results 5858 4Beckman Coulter Announces Third Quarter 2009 Results 5858 5Beckman Coulter Announces Third Quarter 2009 Results 5858 6Beckman Coulter Announces Third Quarter 2009 Results 5858 7Beckman Coulter Announces Third Quarter 2009 Results 5858 8Beckman Coulter Announces Third Quarter 2009 Results 5858 9Beckman Coulter Announces Third Quarter 2009 Results 5858 10Beckman Coulter Announces Third Quarter 2009 Results 5858 11Beckman Coulter Announces Third Quarter 2009 Results 5858 12Beckman Coulter Announces Third Quarter 2009 Results 5858 13Beckman Coulter Announces Third Quarter 2009 Results 5858 14Beckman Coulter Announces Third Quarter 2009 Results 5858 15Beckman Coulter Announces Third Quarter 2009 Results 5858 16Beckman Coulter Announces Third Quarter 2009 Results 5858 17Beckman Coulter Announces Third Quarter 2009 Results 5858 18Beckman Coulter Announces Third Quarter 2009 Results 5858 19Beckman Coulter Announces Third Quarter 2009 Results 5858 20Beckman Coulter Announces Third Quarter 2009 Results 5858 21Beckman Coulter Announces Third Quarter 2009 Results 5858 22Beckman Coulter Announces Third Quarter 2009 Results 5858 23Beckman Coulter Announces Third Quarter 2009 Results 5858 24Beckman Coulter Announces Third Quarter 2009 Results 5858 25Beckman Coulter Announces Third Quarter 2009 Results 5858 26Beckman Coulter Announces Third Quarter 2009 Results 5858 27Beckman Coulter Announces Third Quarter 2009 Results 5858 28Beckman Coulter Announces Third Quarter 2009 Results 5858 29Beckman Coulter Announces Third Quarter 2009 Results 5858 30Beckman Coulter Announces Third Quarter 2009 Results 5858 31Beckman Coulter Announces Third Quarter 2009 Results 5858 32Beckman Coulter Announces Third Quarter 2009 Results 5858 33Beckman Coulter Announces Third Quarter 2009 Results 5858 34Beckman Coulter Announces Third Quarter 2009 Results 5858 35Minnesota High School Tournament Sidelines to be More Secure From Sudden Cardiac Arrest 5856 1Minnesota High School Tournament Sidelines to be More Secure From Sudden Cardiac Arrest 5856 2More Than 30 Defendants Indicted on Prescription Pill Charges in Historic Drug Sweep 5854 1More Than 30 Defendants Indicted on Prescription Pill Charges in Historic Drug Sweep 5854 2
...sistance in HIV-infected patients at the time of H...tients, life expectancy, according to an article i..., now available online. , Resistance to antiretro...eived treatment, is a growing concern. However, ge...for the presence of resistance genes, is not a sta...
... with artificial shark skin could help ships saili...s barnacles on ship hulls is a major cause of incr...in offers a structural design that prevents this s...niversity of Applied Sciences, Bremen, Germany, is...ial shark skin in a new anti-fouling strategy at t...
...rotects us from disease, destroying invading micro...so go haywire for no apparent reason, ganging up o... In thousands of people each year, the immune syst...te structures that allow us to hear. Without warni... hear in one or both ears. Some might get part or ...
Other Biology News:Drug resistance testing in treatment-naive HIV patients is cost-effective 2New Lab Research May Help Those Deafened By Immune System Attack 2New Lab Research May Help Those Deafened By Immune System Attack 3New Lab Research May Help Those Deafened By Immune System Attack 4
Rabbit Anti-cdc42 / Rac Polyclonal Antibody, Unconjugated from Assay Designs/Stressgen Bioreagents
Rabbit Anti-TRPM8 Polyclonal Antibody, Unconjugated from Abcam
Rat Anti-Mouse CD205 (DEC-205) Monoclonal Antibody, Unconjugated, Clone NLDC-145 from Cell Sciences
Rabbit Anti-Herstatin Polyclonal Antibody, Unconjugated from Abcam
Biology Products: